Old Web
English
Sign In
Acemap
>
authorDetail
>
Douglas Neely
Douglas Neely
Medicine
Physical therapy
double blinded
Progressive disease
Pathology
7
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Risk-adapted maintenance therapy (MaintRx) after ASCT in first-line therapy for multiple myeloma (MM).
2017
Journal of Clinical Oncology
Jonathan L. Kaufman
Joanne Willey
Michael E. Williams
Brynn Tiscione
Arden Buettner
Douglas Neely
Mark R. Green
Show All
Source
Cite
Save
Citations (0)
First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents
2014
Blood
Mark R. Green
Michael E. Williams
Joanne Willey
Arden Buettner
Douglas Neely
Maria Lankford
Show All
Source
Cite
Save
Citations (2)
Prospective evaluation of prescribing preferences (PPref) by U.S.-based oncologists in the postdocetaxel mCRPC patient.
2014
Journal of Clinical Oncology
Charles J. Ryan
Mark R. Green
Susan Lynne Britton
Arden Buettner
Maria Lankford
Douglas Neely
Show All
Source
Cite
Save
Citations (0)
Prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) for choice of therapy after failure of first-line FOLFOX plus bevacizumab (FFB) in patients with metastatic colorectal cancer (MCC).
2014
Journal of Clinical Oncology
Johanna C. Bendell
Susan Lynne Britton
Maria Lankford
Arden Buettner
Mark R. Green
Douglas Neely
Mitchell Scharf
Show All
Source
Cite
Save
Citations (0)
1